McCulloch Kevin sold $127K of XERS
McCulloch Kevin (See Remarks) sold 15,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.49 ($0.13M total) on 2026-09-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction is a primary disclosure but of modest scale, offering limited trading insight.
Market read
Minor insider sell; unlikely to move the stock significantly.
What to watch
Potential upcoming corporate events (e.g., trial data) could make the sale more meaningful if disclosed later.
Background
SEC Form 4 filing reports a routine 10b5-1 sale by an officer of Xeris Biopharma.
Ticker impact
Officer Kevin McCulloch sold 15,000 shares of Xeris Biopharma for $127,308 via a 10b5-1 plan.
Limited short-term impact; may cause slight downward bias if market interprets as lack of confidence.
Sale size ($127k) is minor compared to insider's remaining 1.64M shares; typical for routine liquidity needs.
Market effects
No immediate sector impact; biotech sector remains driven by pipeline news.
US market only; negligible regional effect.
Low global relevance.
Counterpoint
Some traders may view any insider sale as a bearish signal, but the small amount and pre-arranged plan dilute that view.
Key entities
- CompanyXeris Biopharma Holdings, Inc.
Biopharma company listed on NASDAQ (XERS).
- InsiderKevin McCulloch
Officer of Xeris Biopharma executing a pre-arranged sale.
